Table III.
Overall survival from diagnosis of 3,132 patients with early-stage mycosis fungoides (Surveillance, Epidemiology, and End Results (SEER) registries 2005-2015)
| 5-year cumulative survival | 95% CI | Adjusted* HR | 95% CI | |
|---|---|---|---|---|
| All | 0.861 | 0.845–0.875 | – | – |
| EORTC stage** | ||||
| IA | 0.873 | 0.856–0.888 | Ref | – |
| IB | 0.833 | 0.791–0.868 | 1.30 | 1.01-1.67 |
| IIA | 0.577 | 0.415–0.709 | 3.47 | 2.29-5.27 |
| Age group (quartile) | ||||
| <45 years | 0.967 | 0.946–0.980 | Ref | – |
| 45–59 years | 0.927 | 0.903–0.946 | 2.64 | 1.60–4.36 |
| 60–70 years | 0.864 | 0.831–0.890 | 5.00 | 3.09–8.08 |
| ≥70 years | 0.647 | 0.601–0.690 | 15.42 | 9.75–24.39 |
| Sex | ||||
| Female | 0.887 | 0.864–0.906 | Ref | – |
| Male | 0.841 | 0.819–0.861 | 1.29 | 1.05–1.58 |
*
Hazard ratio (HR) from Cox proportional hazards models adjusted by the other variables in the table
**
European Organisation for Research and Treatment of cancer (EORTC) stage from Tumour-Node-Metastasis (without blood status); Ref: reference group; CI: confidence interval.